再鼎医药ZLAB财报
Nasdaq · 医疗保健 · 药物制剂
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
主要股东
| 股东 | 持股比例 | 股数 | 变动 | 截至 |
|---|---|---|---|---|
| Wellington Management Group LLP | 11.87% | 118.2M | ▲ +1.05pp | 2024-11-08 |
| S.S. OR | 9.20% | 91.6M | — | 2024-11-14 |
| OF ABOVE PERSONS | 6.20% | 61.2M | ▲ +4.30pp | 2024-02-09 |
| FMR LLC | 3.51% | 34.7M | — | 2024-02-09 |
内部人交易
Net 90d: −$5.36M · buys $32.7K / sells $5.40M时间范围:
类型:
身份:
| 内部人 | 身份 | 类型 | ||||
|---|---|---|---|---|---|---|
| 2026-04-06 | Yajing Chen | Chief Financial Officer | Sell (open market) | 853 | $20.45 | $17.4K |
| 2026-04-06 | Ying Du | Chairperson & CEO | Sell (open market) | 2.7K | $20.45 | $54.2K |
| 2026-04-06 | Edmondson Frazor Titus III | Chief Legal Officer | Sell (open market) | 1.2K | $20.45 | $25.0K |
| 2026-04-06 | Rafael Amado | See Remarks | Sell (open market) | 2.7K | $20.45 | $56.0K |
| 2026-04-06 | Smiley Joshua L | See Remarks | Sell (open market) | 3.0K | $20.45 | $61.7K |
| 2026-04-02 | Smiley Joshua L | See Remarks | Option exercise | 7.1K | — | — |
| 2026-04-02 | Smiley Joshua L | See Remarks | Sell (open market) | 9.6K | $20.39 | $196.0K |
| 2026-04-02 | Yajing Chen | Chief Financial Officer | Option exercise | 2.5K | — | — |
| 2026-04-02 | Yajing Chen | Chief Financial Officer | Sell (open market) | 5.2K | $20.39 | $106.0K |
| 2026-04-02 | Rafael Amado | See Remarks | Option exercise | 5.4K | — | — |
1–10 of 47
第 1 页 / 共 5 页